Suay García, BeatrizGarcía Andrés, MarioMateos Lindemann, María LuisaPérez Gracia, María TeresaUCH. Departamento de FarmaciaUCH. Departamento de Matemáticas, Física y Ciencias TecnológicasProducción Científica UCH 20162019-02-212019-02-212016-05-21Pérez Gracia, MT., Suay García, B., García Andrés, M. & Mateos Lindemann, ML. (2016). Hepatitis E : latest developments in knowledge. Future Microbiology, vol 11, n. 6. DOI: https://doi.org/10.2217/fmb-2016-00121746-0913.1746-0921.http://hdl.handle.net/10637/10001Este artículo se encuentra disponible en la siguiente URL: https://www.futuremedicine.com/doi/10.2217/fmb-2016-0012Este es el post-print del siguiente artículo, Pérez Gracia, MT., Suay García, B., García Andrés, M. & Mateos Lindemann, ML. (2016). Hepatitis E : latest developments in knowledge. Future Microbiology, vol 11, n. 6, que se ha publicado de forma definitiva en https://doi.org/10.2217/fmb-2016-0012This is the peer reviewed version of the following article: Pérez Gracia, MT., Suay García, B., García Andrés, M. & Mateos Lindemann, ML. (2016). Hepatitis E : latest developments in knowledge. Future Microbiology, vol 11, n. 6, which has been published in final form at https://doi.org/10.2217/fmb-2016-0012Hepatitis E, caused by Hepatitis E virus (HEV), is a highly prevalent disease in developing countries. In developed nations, autochthonous HEV infections seem to be an emergent disease. Its clinical manifestations and epidemiology are well known for endemic countries. It has been confirmed that hepatitis E is a zoonosis and that parenteral transmission can also occur. The molecular mechanisms of HEV replication are not fully understood, mostly because there are no efficient cell culture systems. HEV can cause chronic hepatitis in organ transplant recipients and immunocompetent patients. Cases with fulminant hepatitis and other extrahepatic manifestations have also been reported. The diagnosis is based on serological studies and detection of HEV RNA in blood and feces. Treatment with ribavirin and/or pegylated-IFN-α have proven to be successful in some cases. The recently approved/marketed vaccine is a good option in order to prevent this infection.application/pdfenVirus de la Hepatitis E - Vacunación.Hepatitis E - Tratamiento.Hepatitis E - Treatment.Hepatitis E - Vacunación.Vacunas.Hepatitis E virus - Treatment.Hígado - Enfermedades - Tratamiento.Liver - Diseases - Treatment.Virus de la Hepatitis E - Tratamiento.Hepatitis E virus - Vaccination.Hepatitis E - Vaccination.Vaccines.Artículohttps://doi.org/10.2217/fmb-2016-0012https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es